The prevalence of microalbuminuria indifferent hypertensive phenotypes

1. The prevalence of microalbuminuria indifferent hypertensive phenotypes David WJ Armstrong, Michael A Nault, Daniel Brouillard, Murray F Matangi. Kingston Heart Clinic, Kingston, Ontario, Canada and Ontario, Canada Purpose. Results. • Microalbuminuria (30-300mg/L) on a spot sample of urine is a subclinical maker of cardiovascular risk • Microalbuminuria is also an important prognostic marker for predicting kidney disease in patients with diabetes mellitus and hypertension • The purpose of our investigation was to determine the differences in the amount of microalbuminuria in patients with different hypertensive phenotypes as determined by 24hr ambulatory blood pressure monitoring, (ABPM). Methods. • BLOODfile and 24hrBPfile, the biochemical and 24hrABPM modules of CARDIOfile™, our cardiology database, was searched for all patients who had both an ABPM and measurement of microalbuminuria within 90 days of each measurement. • Microalbuminuria was defined as <400mg/l in a spot urine specimen. There were 535 patients who fulfilled these criteria and were used in this analysis. • One-way ANOVA was used to determine significance between all means. • Tukey-Kramer comparisons test was used to determine differences between groups. Conclusions. • It is clear from these data that patients with uncontrolled hypertension have significantly more microalbuminuria than other hypertensive phenotypes. • The data for patients with masked hypertension and hypertension with white coat effect are interesting but did not reach statistical significance using the Tukey-Kramer comparisons testing between groups. • More data collection is required to see if those with both masked hypertension and hypertension with white coat effect will eventually become statistically significant.